Yuyang Yue, Guangqi An, Shuxia Cao, Xiangdan Li, Liping Du, Dongyuan Xu, Toufeng Jin, Lan Liu
{"title":"PLEKHA4 upregulation regulates KIRC cell proliferation through β‑catenin signaling.","authors":"Yuyang Yue, Guangqi An, Shuxia Cao, Xiangdan Li, Liping Du, Dongyuan Xu, Toufeng Jin, Lan Liu","doi":"10.3892/mmr.2024.13395","DOIUrl":null,"url":null,"abstract":"<p><p>In the present study, pleckstrin homology domain‑containing family A member 4 (PLEKHA4) was identified as being upregulated in renal cell carcinoma, particularly within the kidney renal clear cell carcinoma (KIRC) subtype. The present study conducted bioinformatics analysis, Cell Counting Kit‑8 and cell migration assays, flow cytometry, western blotting and <i>in vivo</i> experiments with the aim of uncovering the role of PLEKHA4 in β‑catenin signaling in KIRC cells. Notably, PLEKHA4 upregulation was revealed to be associated with enhanced cell proliferation, indicating its potential role as an oncogene in KIRC. Mechanistically, knockdown of PLEKHA4 in KIRC cells led to decreased β‑catenin signaling and cyclin D1 expression and the induction of cell cycle arrest at the G1/S phase, suggesting that PLEKHA4 facilitated tumorigenesis through modulation of the Wnt/β‑catenin pathway. PLEKHA4 knockdown also inhibited cell viability, migration and colony formation, further emphasizing its role in cancer progression. Notably, overexpression of PLEKHA4 activated Wnt/β‑catenin signaling, reinforcing its role in promoting β‑catenin nuclear translocation and signaling activity. The present findings suggested that PLEKHA4 could serve as a potential therapeutic target for KIRC; inhibiting PLEKHA4 or modulating Wnt/β‑catenin signaling could provide new avenues for treatment strategies in KIRC.</p>","PeriodicalId":18818,"journal":{"name":"Molecular medicine reports","volume":"31 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular medicine reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/mmr.2024.13395","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
In the present study, pleckstrin homology domain‑containing family A member 4 (PLEKHA4) was identified as being upregulated in renal cell carcinoma, particularly within the kidney renal clear cell carcinoma (KIRC) subtype. The present study conducted bioinformatics analysis, Cell Counting Kit‑8 and cell migration assays, flow cytometry, western blotting and in vivo experiments with the aim of uncovering the role of PLEKHA4 in β‑catenin signaling in KIRC cells. Notably, PLEKHA4 upregulation was revealed to be associated with enhanced cell proliferation, indicating its potential role as an oncogene in KIRC. Mechanistically, knockdown of PLEKHA4 in KIRC cells led to decreased β‑catenin signaling and cyclin D1 expression and the induction of cell cycle arrest at the G1/S phase, suggesting that PLEKHA4 facilitated tumorigenesis through modulation of the Wnt/β‑catenin pathway. PLEKHA4 knockdown also inhibited cell viability, migration and colony formation, further emphasizing its role in cancer progression. Notably, overexpression of PLEKHA4 activated Wnt/β‑catenin signaling, reinforcing its role in promoting β‑catenin nuclear translocation and signaling activity. The present findings suggested that PLEKHA4 could serve as a potential therapeutic target for KIRC; inhibiting PLEKHA4 or modulating Wnt/β‑catenin signaling could provide new avenues for treatment strategies in KIRC.
本研究发现,pleckstrin homology domain-containing family A member 4 (PLEKHA4)在肾细胞癌中上调,尤其是在肾透明细胞癌(KIRC)亚型中。本研究进行了生物信息学分析、细胞计数试剂盒-8和细胞迁移测定、流式细胞术、Western印迹和体内实验,旨在揭示PLEKHA4在KIRC细胞β-catenin信号转导中的作用。值得注意的是,PLEKHA4的上调与细胞增殖增强有关,这表明它在KIRC中可能扮演着癌基因的角色。从机理上讲,在KIRC细胞中敲除PLEKHA4会导致β-catenin信号转导和细胞周期蛋白D1表达减少,并诱导细胞周期停滞在G1/S期,这表明PLEKHA4通过调节Wnt/β-catenin通路促进了肿瘤发生。敲除 PLEKHA4 还能抑制细胞活力、迁移和集落形成,进一步强调了它在癌症进展中的作用。值得注意的是,PLEKHA4的过表达激活了Wnt/β-catenin信号转导,加强了其促进β-catenin核转位和信号转导活性的作用。本研究结果表明,PLEKHA4可作为KIRC的潜在治疗靶点;抑制PLEKHA4或调节Wnt/β-catenin信号可为KIRC的治疗策略提供新途径。
期刊介绍:
Molecular Medicine Reports is a monthly, peer-reviewed journal available in print and online, that includes studies devoted to molecular medicine, underscoring aspects including pharmacology, pathology, genetics, neurosciences, infectious diseases, molecular cardiology and molecular surgery. In vitro and in vivo studies of experimental model systems pertaining to the mechanisms of a variety of diseases offer researchers the necessary tools and knowledge with which to aid the diagnosis and treatment of human diseases.